Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;35(9):e15706.
doi: 10.1111/dth.15706. Epub 2022 Jul 19.

Treatment of pediatric cutaneous leishmaniasis with liposomal amphotericin B

Tugba Erat  1 , Isa An  2
Affiliations

Treatment of pediatric cutaneous leishmaniasis with liposomal amphotericin B

Tugba Erat et al. Dermatol Ther. 2022 Sep.

Abstract

The use of liposomal amphotericin B (L-AmB) in the treatment of cutaneous leishmaniasis (CL) is increasing. However, few data are available regarding the efficacy and safety of L-AmB in pediatric CL patients. Our aim in this study is to evaluate the efficacy and safety of L-AmB in pediatric CL patients. Pediatric patients admitted to a tertiary training and research hospital in a hyperendemic region for CL between January 2019 and May 2021 and receiving L-AmB therapy for CL were included in this retrospective study. L-AmB treatment was administered as 3 mg/kg for 5 consecutive days and on the 10th day, in a total of 6 doses (18 mg/kg total dose). A total of 52 pediatric patients who received L-AmB therapy for CL were included in the study. In the follow-up 3 months after L-AmB treatment, 16 (31%) patients showed complete clinical recovery, while treatment failure was detected in 36 (69%) patients. In conclusion, considering the low treatment success rate in our study, we think that the L-AmB dose used in our study is not an appropriate treatment option for the treatment of pediatric CL patients. However, we think that prospective studies with a large number of patients treated with higher doses of L-AmB and in whom the causative agents of CL were determined are needed.

Keywords: cutaneous leishmaniasis; liposomal amphotericin B; pediatric.

PubMed Disclaimer

References

REFERENCES

    1. Uzun S, Gürel MS, Durdu M, et al. Clinical practice guidelines for the diagnosis and treatment of cutaneous leishmaniasis in Turkey. Int J Dermatol. 2018;57(8):973-982.
    1. An I, Aksoy M, Ozturk M, et al. Atypical and unusual morphological variants of cutaneous leishmaniasis. Int J Clin Pract. 2021;75(3):e13730.
    1. Harman M. Cutaneous leishmaniasis. Turk J Dermatol. 2015;9:168-176.
    1. WHO | World Health Organization, Leishmaniasis, Accessed June 15, 2022, https://www.who.int/health-topics/leishmaniasis/#tab=tab_1.
    1. Wijnant GJ, Bocxlaer KV, Francisco AF, et al. Local skin ınflammation in cutaneous leishmaniasis as a source of variable pharmacokinetics and therapeutic efficacy of liposomal amphotericin B. Antimicrob Agents Chemother. 2018;62:e00631-e00618.

LinkOut - more resources